CATALAYER NEWS
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Source: CNBC Top · 2026-07-29
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
MORE FROM CNBC TOP
FIFA is embroiled in a $20 billion World Cup controversy. Here's what's going on
2026-07-29
OpenAI's rogue agent compromised a customer at a second tech firm: Reuters
2026-07-29
Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
2026-07-29
Jim Cramer's top 10 things to watch in the stock market Wednesday
2026-07-29
We're exiting our position in a household products giant after a soft quarter
2026-07-29
RELATED ON CATALAYER
Mentioned Tickers
$NVO · Novo NordiskRELATED MARKETS
Prediction Markets